PURPOSE: Optimal management of isolated local recurrences after stereotactic body radiation therapy (SBRT) for early non-small cell lung cancer (NSCLC) is unknown and literature describing repeat SBRT for in-field recurrences after initial SBRT are sparse. We investigate the safety and efficacy of salvage SBRT for isolated local failures after initial SBRT for NSCLC. METHODS/MATERIALS: Patients receiving SBRT for isolated local recurrence after initial SBRT for early NSCLC were identified using a prospective registry. Both courses were 3-5 fractions with a biologically effective dose (BED10) of ≥100 Gy. Local failure was defined as within 1 cm of the initial planning target volume (PTV) or an overlap of the ≥25% isodose lines of the first and second treatments. Failures >1 cm beyond the PTV and without ≥25% overlap, or with additional recurrence sites were excluded. Kaplan-Meier analysis was used to estimate survival. RESULTS: A total 21 patients receiving salvage SBRT from 2008 to 2017 were identified. Median interval from initial SBRT to salvage SBRT was 23 months (7-52). Six patients (29%) had central tumors. Median follow-up time from salvage SBRT was 24 months (3-60). Median overall survival after salvage was 39 months. After reirradiation, two-year primary tumor control was 81%, regional nodal control was 89%, distant control was 75% and overall survival was 68%. Grade 2 pneumonitis occurred in 2 patients (10%) and grade 2 chest wall toxicity in 4 patients (19%). No grade 3+ toxicity was observed. CONCLUSIONS: Salvage SBRT for isolated local failures after initial SBRT appears safe, with low treatment-related toxicity and encouraging rates of tumor control.
PURPOSE: Optimal management of isolated local recurrences after stereotactic body radiation therapy (SBRT) for early non-small cell lung cancer (NSCLC) is unknown and literature describing repeat SBRT for in-field recurrences after initial SBRT are sparse. We investigate the safety and efficacy of salvage SBRT for isolated local failures after initial SBRT for NSCLC. METHODS/MATERIALS: Patients receiving SBRT for isolated local recurrence after initial SBRT for early NSCLC were identified using a prospective registry. Both courses were 3-5 fractions with a biologically effective dose (BED10) of ≥100 Gy. Local failure was defined as within 1 cm of the initial planning target volume (PTV) or an overlap of the ≥25% isodose lines of the first and second treatments. Failures >1 cm beyond the PTV and without ≥25% overlap, or with additional recurrence sites were excluded. Kaplan-Meier analysis was used to estimate survival. RESULTS:A total 21 patients receiving salvage SBRT from 2008 to 2017 were identified. Median interval from initial SBRT to salvage SBRT was 23 months (7-52). Six patients (29%) had central tumors. Median follow-up time from salvage SBRT was 24 months (3-60). Median overall survival after salvage was 39 months. After reirradiation, two-year primary tumor control was 81%, regional nodal control was 89%, distant control was 75% and overall survival was 68%. Grade 2 pneumonitis occurred in 2 patients (10%) and grade 2 chest wall toxicity in 4 patients (19%). No grade 3+ toxicity was observed. CONCLUSIONS: Salvage SBRT for isolated local failures after initial SBRT appears safe, with low treatment-related toxicity and encouraging rates of tumor control.
Authors: Patrick Kelly; Peter A Balter; Neal Rebueno; Hadley J Sharp; Zhongxing Liao; Ritsuko Komaki; Joe Y Chang Journal: Int J Radiat Oncol Biol Phys Date: 2010-04-08 Impact factor: 7.038
Authors: Jeremy M Kilburn; Jeffrey G Kuremsky; A William Blackstock; Michael T Munley; William T Kearns; William H Hinson; James F Lovato; Antonius A Miller; William J Petty; James J Urbanic Journal: Radiother Oncol Date: 2014-01-17 Impact factor: 6.280
Authors: Robert W Mutter; Fan Liu; Andres Abreu; Ellen Yorke; Andrew Jackson; Kenneth E Rosenzweig Journal: Int J Radiat Oncol Biol Phys Date: 2011-08-23 Impact factor: 7.038
Authors: Hui Liu; Xu Zhang; Yevgeniy Y Vinogradskiy; Stephen G Swisher; Ritsuko Komaki; Joe Y Chang Journal: Int J Radiat Oncol Biol Phys Date: 2012-04-27 Impact factor: 7.038
Authors: Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth Journal: Lancet Oncol Date: 2015-05-13 Impact factor: 41.316
Authors: Waqar Haque; Vivek Verma; Praveen Polamraju; Andrew Farach; E Brian Butler; Bin S Teh Journal: Radiother Oncol Date: 2018-07-18 Impact factor: 6.280
Authors: Hann-Hsiang Chao; Abigail T Berman; Charles B Simone; Christine Ciunci; Peter Gabriel; Haibo Lin; Stefan Both; Corey Langer; Kristi Lelionis; Ramesh Rengan; Stephen M Hahn; Kiran Prabhu; Marcio Fagundes; William Hartsell; Rosemarie Mick; John P Plastaras Journal: J Thorac Oncol Date: 2016-11-05 Impact factor: 15.609
Authors: Neal E Dunlap; Jing Cai; Gregory B Biedermann; Wensha Yang; Stanley H Benedict; Ke Sheng; Tracey E Schefter; Brian D Kavanagh; James M Larner Journal: Int J Radiat Oncol Biol Phys Date: 2009-05-08 Impact factor: 7.038
Authors: Caroline John; Riccardo Dal Bello; Nicolaus Andratschke; Matthias Guckenberger; Judit Boda-Heggemann; Eleni Gkika; Frederick Mantel; Hanno M Specht; Carmen Stromberger; Franz Zehentmayr; Oliver Blanck; Panagiotis Balermpas Journal: Sci Rep Date: 2021-02-25 Impact factor: 4.379